Ovarian Carcinoma Clinical Trials in New York, New York
16 recruitingNew York, New York
Showing 1–16 of 16 trials
Recruiting
Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 2
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
Recurrent Ovarian CarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube Carcinoma+1 more
National Cancer Institute (NCI)165 enrolled296 locationsNCT05554328
Recruiting
Phase 1
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
Recurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Platinum-Resistant Ovarian Carcinoma
National Cancer Institute (NCI)42 enrolled27 locationsNCT04633239
Recruiting
Phase 3
A Study of Intra-operative Imaging in Women With Ovarian Cancer
Ovarian CancerOvarian Carcinoma
Memorial Sloan Kettering Cancer Center310 enrolled9 locationsNCT04878094
Recruiting
National Cancer Institute "Cancer Moonshot Biobank"
Ovarian CarcinomaEsophageal CarcinomaGastric Carcinoma+26 more
National Cancer Institute (NCI)1,600 enrolled152 locationsNCT04314401
Recruiting
Phase 2
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Ovarian CancerOvarian CarcinomaFallopian Tube Cancer+7 more
Memorial Sloan Kettering Cancer Center86 enrolled7 locationsNCT06290193
Recruiting
Not Applicable
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
NRG Oncology1,956 enrolled549 locationsNCT04251052
Recruiting
Phase 3
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Ovarian CarcinomaOvarian High Grade Serous AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+6 more
NRG Oncology880 enrolled676 locationsNCT06580314
Recruiting
Phase 3
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
Stage IV Ovarian Cancer AJCC v8Stage IIIC Ovarian Cancer AJCC v8Advanced Ovarian Carcinoma+22 more
M.D. Anderson Cancer Center580 enrolled19 locationsNCT04575935
Recruiting
Phase 1Phase 2
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ovarian CarcinomaColorectal CarcinomaMelanoma+19 more
Children's Oncology Group147 enrolled21 locationsNCT04851119
Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Breast CancerUrothelial CarcinomaSoft Tissue Sarcoma+2 more
Avacta Life Sciences Ltd158 enrolled9 locationsNCT04969835
Recruiting
Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+11 more
Daiichi Sankyo740 enrolled84 locationsNCT06172478
Recruiting
Phase 1Phase 2
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
Platinum-refractory Ovarian Carcinoma
TILT Biotherapeutics Ltd.29 enrolled3 locationsNCT05271318
Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Bladder CarcinomaEsophageal CarcinomaNon-small Cell Lung Cancer+13 more
Guardant Health, Inc.2,020 enrolled57 locationsNCT05059444
Recruiting
Not Applicable
A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
Ovarian CancerOvarian CarcinomaPrimary Peritoneal Carcinoma+11 more
Memorial Sloan Kettering Cancer Center35 enrolled7 locationsNCT05429970
Recruiting
Phase 2
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
Metastatic Malignant Solid NeoplasmRecurrent Ovarian CarcinomaStage III Ovarian Cancer AJCC v8+17 more
Rutgers, The State University of New Jersey40 enrolled2 locationsNCT03428802